Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IMRN

Immuron Limited ADR

Nov 07 • 04:00PM ET

1.64

-0.02 -1.20 %

Healthcare • Biotechnology • Australia • NASD

Peers: DVAX ALT OCGN BCRX AQST GERN TFFP MCRB AVIR MNOV

Index	-	P/E	-	EPS (ttm)	-0.58	Insider Own	-	Shs Outstand	5.85M	Perf Week	-13.68%
Market Cap	11.04M	Forward P/E	-	EPS next Y	-0.01	Insider Trans	-	Shs Float	3.25M	Perf Month	-23.36%
Enterprise Value	7.20M	PEG	-	EPS next Q	-0.01	Inst Own	0.34%	Short Float	0.80%	Perf Quarter	-1.20%
Income	-3.38M	P/S	2.33	EPS this Y	97.54%	Inst Trans	35.22%	Short Ratio	0.16	Perf Half Y	-14.14%
Sales	4.73M	P/B	1.81	EPS next Y	12.89%	ROA	-39.65%	Short Interest	0.03M	Perf YTD	-3.53%
Book/sh	0.90	P/C	2.87	EPS next 5Y	-	ROE	-49.00%	52W High	2.48 -33.95%	Perf Year	-14.58%
Cash/sh	0.57	P/FCF	-	EPS past 3/5Y	-17.17% -5.64%	ROIC	-63.83%	52W Low	1.42 15.49%	Perf 3Y	-19.21%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	104.12% 22.82%	Gross Margin	65.42%	Volatility	13.43% 8.23%	Perf 5Y	-91.80%
Dividend TTM	-	EV/Sales	1.52	EPS Y/Y TTM	26.84%	Oper. Margin	-92.59%	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.19	Sales Y/Y TTM	47.17%	Profit Margin	-71.37%	RSI (14)	36.43	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.09	EPS Q/Q	47.15%	SMA20	-19.40%	Beta	0.79	Target Price	4.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	24.59%	SMA50	-17.24%	Rel Volume	0.75	Prev Close	1.66
Employees	-	LT Debt/Eq	0.00	Earnings	Aug 28 AMC	SMA200	-11.77%	Avg Volume	165.78K	Price	1.64
IPO	Mar 02, 2017	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	124,651	Change	-1.20%

Nov-05-25 06:00AM	Immuron IMM-529 IND approved by FDA (GlobeNewswire) -12.72%
Oct-31-25 06:00AM	Immuron Announces Clinical Trial Update (GlobeNewswire) -5.94%
Oct-17-25 11:07AM	Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target (Newsfile)
Oct-13-25 06:00AM	Immuron Q1 FY26 YoY growth (GlobeNewswire)
Oct-08-25 06:00AM	Immuron Submits IMM-529 IND to FDA (GlobeNewswire)
06:00AM	Loading…
Oct-02-25 06:00AM	Immuron Letter to Shareholders - Projects Update (GlobeNewswire) +7.86%
Sep-30-25 03:01PM	Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales (Insider Monkey)
Aug-26-25 10:29PM	Immuron partners with InvestorHub (GlobeNewswire)
Jul-17-25 06:00AM	Immuron - FY25 global sales exceed projection, up 49% on prior year (GlobeNewswire)
May-30-25 06:00AM	Immuron Letter to Shareholders: Projects Update (GlobeNewswire)
Apr-10-25 06:00PM	Immuron Travelan highest sales in history (GlobeNewswire)
Mar-05-25 06:00AM	Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) (GlobeNewswire) +8.20%
Feb-18-25 07:00AM	Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now (GlobeNewswire)
Jan-17-25 06:00AM	Immuron Travelan continued strong sales growth (GlobeNewswire) +8.59%
Jan-15-25 06:00AM	Immuron Announces New Research Collaboration targeting Antimicrobial Resistance (GlobeNewswire)
06:00AM	Loading…
Jan-14-25 06:00AM	Immuron Announces Travelan Clinical Trial Update (GlobeNewswire)
Dec-06-24 09:17AM	UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
08:35AM	Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th (GlobeNewswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire)
08:35AM	Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th (GlobeNewswire)
Dec-02-24 06:00AM	Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th (GlobeNewswire)
Nov-21-24 06:33PM	Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event (GlobeNewswire)
Nov-18-24 08:30AM	Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event (ACCESSWIRE)
Oct-30-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now (GlobeNewswire)
Oct-29-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now (GlobeNewswire)
Oct-16-24 06:00AM	Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference (GlobeNewswire) +7.49%
Oct-15-24 06:00AM	Immuron Travelan continued strong sales growth (GlobeNewswire) -15.76%
Oct-04-24 06:30AM	NMRC Reports Results for Campylobacter Controlled Human Infection Model Study (GlobeNewswire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire) +11.92%
11:54AM	Loading…
Sep-05-24 11:54AM	Immuron Plans Phase 2 Trial for IMM-529 following FDA review (GlobeNewswire)
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire) +8.06%
Aug-16-24 06:00AM	Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan (GlobeNewswire)
Aug-15-24 06:14PM	Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference (GlobeNewswire)
Aug-07-24 06:00AM	Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect (GlobeNewswire)
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-15-24 08:00AM	Immuron announces record Travelan sales globally, Australia and USA (GlobeNewswire) +6.36%
Jul-02-24 06:00AM	Immuron requests pre-IND meeting for IMM-529 with FDA filing (GlobeNewswire)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-05-24 06:00AM	Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference (GlobeNewswire)
May-31-24 06:00AM	Immuron CEO Steven Lydeamore to present at Peak Sky High (GlobeNewswire)
06:00AM	Immuron Board Changes (GlobeNewswire)
May-08-24 07:50AM	Presenting on the Emerging Growth Conference 70 Day 2 on May 9 Register Now (GlobeNewswire)
May-07-24 07:00AM	Presenting on the Emerging Growth Conference 70 Day 1 on May 8 Register Now (GlobeNewswire)
06:00AM	Immuron Limited to Present at the Emerging Growth Conference (GlobeNewswire)
May-03-24 06:00AM	Immuron Director Resignation (GlobeNewswire)
Apr-15-24 06:00AM	Immuron to host Live Virtual Event (GlobeNewswire)
Apr-10-24 06:00AM	Immuron Travelan sales continued strong growth (GlobeNewswire) +8.53%
Mar-07-24 06:00AM	Immuron Announces Positive Results Support Travelan progress to Phase 3 Clinical Trials in the US (GlobeNewswire) +175.74%
Feb-21-24 06:00AM	Immuron Presentation Australian Biologics Festival 2024 (GlobeNewswire)
Feb-13-24 06:00AM	Immuron achieves record Travelan sales (GlobeNewswire)
Feb-08-24 06:00AM	Immuron CEO, Steven Lydeamore Investor Webinar Presentation (GlobeNewswire)
Jan-16-24 06:00AM	Immuron achieves record half yearly Travelan sales (GlobeNewswire)
Dec-22-23 06:00AM	Immuron Clinical Trials Update (GlobeNewswire)
Dec-04-23 06:00AM	Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study (GlobeNewswire)
Nov-28-23 06:33AM	Immuron CEO, Steven Lydeamore Investor Webinar Presentation (GlobeNewswire) +5.70%
Nov-13-23 06:00PM	Immuron CEO Steven Lydeamore Investor Webinar Presentation (GlobeNewswire) +6.25% +11.18%
Oct-30-23 07:21AM	Immuron CEO Steven Lydeamore presented at AusBioInvest (GlobeNewswire)
Oct-18-23 06:00AM	Immuron Announces Travelan Clinical Study Cohort 2 commences (GlobeNewswire)
Oct-11-23 06:00AM	Immuron achieves record quarterly Travelan sales (GlobeNewswire)
Sep-18-23 07:30AM	Immuron Limited Announces Participation in the LD Micro Main Event XVI (Newsfile)
Sep-14-23 01:30PM	Immuron hails record monthly sales of Travelan (News Direct)
Sep-13-23 06:00AM	Immuron achieves record monthly Travelan® sales (GlobeNewswire)
Sep-11-23 06:00AM	Immuron CEO, Steven Lydeamore to present at H.C. Wainwright (GlobeNewswire)
Aug-23-23 08:30AM	Planet MicroCap Review Magazine for Summer 2023 Now Online (ACCESSWIRE)
Aug-14-23 06:00AM	Immuron to present at the Military Health System Research Symposium (GlobeNewswire)
Jul-26-23 02:45PM	Immuron welcomes launch of Travelan on Amazon US (News Direct)
Jul-25-23 06:00AM	Immuron Announces First Patients Enrolled in Travelan® Clinical Study (GlobeNewswire)
Jul-24-23 06:00AM	Immuron CEO, Steven Lydeamore to present at Bioshares (GlobeNewswire)
Jul-19-23 08:30AM	Immuron Ltd. Describes How their Gastrointestinal and Digestive Health Immune Supplements Work + FY23 Sales Announcement in New CEO Video Interview on Planet MicroCap (ACCESSWIRE)
Jul-11-23 06:00AM	Immuron Business Update - Ateria Health launches Juvia in Australia (GlobeNewswire)
Jul-05-23 06:00AM	Immuron FY23 Sales increase 136% on FY22 Sales (GlobeNewswire) +7.44%
Jun-30-23 06:00AM	Immuron Chairman Transition (GlobeNewswire) +6.31%
Jun-22-23 06:00AM	Immuron Business Update: Letter to Shareholders (GlobeNewswire)
May-30-23 06:00AM	Immuron Initiates Recruitment of Travelan® Clinical Study (GlobeNewswire)
May-16-23 07:30AM	Immuron Limited Announces Participation in the LD Micro Invitational XIII (Newsfile) +5.80%
May-08-23 01:11PM	FDA Lifts Clinical Hold From Immuron's New Campylobacter ETEC Therapeutic Study (Benzinga) +43.32%
06:00AM	Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation (GlobeNewswire)
May-02-23 06:00AM	Immuron CEO, Steven Lydeamore to present at Coffee Microcaps (GlobeNewswire) -9.76%
Apr-19-23 06:00AM	Immuron Q3 FY23 Business Update Presentation (GlobeNewswire) -10.65%
Apr-11-23 06:00AM	Q3 FY23 Business Update Webinar Notification (GlobeNewswire)
Apr-06-23 06:00AM	Immuron Q3 Sales reach 150% of 1H Sales (GlobeNewswire)
Feb-15-23 06:00AM	Immuron CEO, Steven Lydeamore to host an investor webinar (GlobeNewswire)
Jan-25-23 06:00AM	Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic (GlobeNewswire)
Jan-18-23 05:00AM	US Department of Defense Uniformed Services University Clinical Evaluation of Travelan Achieves 150 Recruitment Milestone (GlobeNewswire)
Jan-17-23 07:10AM	Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease (GlobeNewswire)
Dec-23-22 06:00AM	Immuron Receives FDA Approval for Travelan IND Application (GlobeNewswire) +18.63%
Dec-05-22 06:00AM	Immuron Submits IND Application To FDA for Travelan (GlobeNewswire) +6.93%
Nov-16-22 07:00AM	Immuron completes strategic investment in leading gut health biotech Ateria Health (GlobeNewswire)
Oct-26-22 06:00AM	Immuron CEO, Steven Lydeamore to present at AusBioInvest (GlobeNewswire)
Oct-13-22 10:28AM	Immuron Announces Strategic Investment In UK-Based Gut Health Company (Benzinga) +5.24%
06:00AM	Immuron strategic investment in leading gut health biotech Ateria Health (GlobeNewswire)
Oct-04-22 06:00AM	Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron (GlobeNewswire) +12.34%
Aug-29-22 07:00AM	Immuron CEO, Steven Lydeamore, to host an investor webinar (GlobeNewswire)
Aug-19-22 07:23AM	Immuron Pulls Plug On COVID-19 Treatment Hopeful, Citing Changing Landscape (Benzinga)
06:00AM	Immuron Update on IMM-124E SARS-CoV-2 Research (GlobeNewswire)
Jul-26-22 07:07AM	Immuron's IND Application For Bacterial Infection Candidate Placed On Clinical Hold (Benzinga) -5.18%
06:00AM	Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic (GlobeNewswire)

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group's R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMRN

Immuron Limited ADR

Upgrade your FINVIZ experience